Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature by Dammrich, Daniel J et al.
CASE REPORT Open Access
Efficacy of sorafenib, a multi-tyrosine kinase
inhibitor, in an adenoid cystic carcinoma
metastatic to the lung: case report and review
of literature
Daniel J Dammrich
*, Edgardo S Santos and Luis E Raez
Abstract
Introduction: Treatment for squamous cell carcinoma of the head and neck has significantly improved with the
addition of cetuximab, a monoclonal antibody against the epidermal growth factor receptor, to conventional
cytotoxic agents. The most significant aspect of this treatment approach is the proof that head and neck cancers
are suitable for targeted therapies as has been shown in other malignancies. Unfortunately, there are other rare
histologic types of head and neck cancer such as adenocarcinoma and adenoid cystic carcinoma. The latter has
traditionally been considered to be chemotherapy resistant and surgical resection with or without adjuvant
radiation therapy has been the rule as far as treatment is concerned. The course of adenoid cystic carcinoma
ranges from indolent to aggressive; however, most patients succumb to the disease as a result of distant
metastases. This clinical scenario poses a challenge to oncologists. Several conventional chemotherapy regimens
and novel targeted agents have been tried in this rare histologic subtype without success.
Case presentation: In this case report, we present a 59-year-old Caucasian female with refractory adenoid cystic
carcinoma of the maxilla metastatic to the lung that responded to sorafenib, a novel multi-tyrosine kinase inhibitor,
which targets angiogenesis, Raf kinase pathway, platelet-derived growth factor Ret, and c-Kit.
Conclusion: This case illustrates the possibility that this chemoresistant tumor may need the inhibition or blocking
of several oncogenic pathways. Certainly, it is imperative that more studies are done in this special population
trying to identify tumorigenesis mechanisms that may be upregulated in this malignancy and could be potential
targets for therapeutic development.
Introduction
Adenoid cystic carcinoma (ACC) of the head and neck
is an uncommon malignancy that accounts for approxi-
mately 10% of all neoplasms of the salivary glands [1].
While the parotid gland is the most common site of ori-
gin for these tumors, they can occur in any of the major
or minor salivary glands. The major salivary glands
include the parotid, submandibular and sublingual, and
the minor salivary glands can be found throughout the
oral and nasal cavities and in the paranasal sinuses. On
histological analysis, ACC has three recognized growth
patterns: cribriform, tubular and solid.
These tumors are usually slow growing and have a
propensity for local recurrence, perineural invasion and,
eventually, distant metastasis, especially in the lung and
bones. A paranasal location, perineural invasion, solid
histology, high stage, and positive margins after surgery
all predict worse overall survival (OS). Although OS in
these patients is reported as quite high at five years (50-
90%), the 10- and 15-year survival rates are much lower
(25-67%) [2]. In addition, once metastatic lesions are
identified, the average survival is between 20 and 32
months depending on the location of the metastasis [1].
Radical excision followed by radiotherapy is generally
considered to be the initial therapy of choice in patients
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distant metastasis occur frequently. Unfortunately, the
role of chemotherapy and targeted agents is still poorly
defined in these patients. Several chemotherapy agents
and targeted therapies have been studied, however most
of these have been looked at in small retrospective stu-
dies and the results have usually been disappointing.
The aim of this case report is to present a patient with
metastatic ACC who achieved disease stabilization on
sorafenib, after experiencing disease progression on
two different lines of palliative chemotherapy. Sorafenib
is a multi-tyrosine kinase inhibitor (mTKI), which is
approved as first-line therapy for renal cell carcinoma,
hepatoma and gastrointestinal stromal tumors. To the
best of our knowledge there are no reports of the use of
sorafenib in patients with metastatic ACC.
Case presentation
A 59-year-old Caucasian female presented five years
prior to the presentation of this case report with symp-
toms of chronic sinusitis and, upon biopsy, was found
to have ACC in her right inferior turbinate and right
maxillary sinus tissue. The work-up for metastatic dis-
ease at that time, including computed tomography with
positron emission tomography (CT/PET), was negative.
She underwent surgical resection of this neoplasm
shortly after diagnosis and two months later received
adjuvant radiation therapy for one month. She did not
experience any signs or symptoms of local recurrence or
distant metastasis until a surveillance CT/PET scan was
performed three years after her initial presentation
(Figures 1 and 2), which revealed multiple bilateral lung
masses. A biopsy of one of her right lung lesions
confirmed the diagnosis of metastatic ACC. At this
time, these lesions were deemed unresectable and
she was referred to medical oncology for palliative
chemotherapy.
Our patient was initiated on palliative chemotherapy
with CAP regimen (cisplatinum 50 mg/m
2, Adriamycin
(doxorubicin) 50 mg/m
2, and cyclophosphamide 500 mg/
m
2) for six cycles. She experienced progression of the dis-
ease on therapy (Figure 3) and was switched to second-
line therapy combining carboplatin (area under the con-
centration curve = 5) and docetaxel (75 mg/m
2). She was
preparing to start cycle three of carboplatin and doce-
taxel, however she was found to be pancytopenic, includ-
ing grade three thrombocytopenia. The third cycle of
chemotherapy was postponed and she was transfused
with packed red blood cells and placed on growth factor
support. During this delay restaging was performed, and
once again she had experienced progression of the dis-
ease (Figure 4). After failing two lines of palliative che-
motherapy, she was initiated on sorafenib at 400 mg
orally twice a day. Sorafenib was chosen in this setting
because it is an easily administered oral medication with
Figure 1 PET/CT scan demonstrating metastatic disease before
any systemic therapy was initiated.
Figure 2 PET/CT scan demonstrating metastatic disease before
any systemic therapy was initiated.
Figure 3 CT scan demonstrating progression of disease after
first line palliative chemotherapy with the CAP regimen.
Dammrich et al. Journal of Medical Case Reports 2011, 5:483
http://www.jmedicalcasereports.com/content/5/1/483
Page 2 of 4a favorable side effect profi l ea n dh a saw i d ev a r i e t yo f
molecular targets. A surveillance CT/PET scan performed
after two cycles of this therapy revealed stable disease, a
clinical response that could not be attained with prior
conventional cytotoxic agents (Figure 5). This response
was based on the Response Evaluation Criteria in Solid
Tumors (RECIST) [3]. According to RECIST, stable dis-
ease is defined as neither partial response, which is a 30%
decrease in the sum of the two longest diameters of the
tumor, nor progressive disease, which is a 20% increase
in the sum of the two longest diameters of the tumor.
Our patient did require a dose reduction of sorafenib of
12.5% due to the fact that she experienced hand-foot syn-
drome, which consists of reddening, swelling, numbness
and desquamation on the palms and soles that can occur
after chemotherapy in cancer patients. She also experi-
enced occasional epistaxis. Otherwise, our patient has tol-
erated sorafenib well and continues on it due to disease
stabilization for six months at the time of writing.
Discussion
Sorafenib, an mTKI, is used in the treatment of
advanced renal cell carcinoma and hepatocellular carci-
noma. It has been shown to have activity against Raf
kinase, vascular endothelial growth factor (VEGF) recep-
tor 2, platelet derived growth factor receptor, Flt-3, Ret
and c-Kit. Based on our review of the literature, we did
not find any cases of ACC treated successfully with
sorafenib.
The ideal treatment for metastatic ACC remains elu-
sive; several single agents and combined chemotherapy
regimens have been studied. Evidence suggests that sin-
gle agent activity is strongest with platinum, 5-fluorour-
acil and anthracyclines, and that the most consistent
response rates are achieved in combination with plati-
num, anthracyclines and alkylating agents [4]. Unfortu-
nately, this response is often short-lived, as it was in this
patient. Due to these results, there is no standard ther-
apy for recurrent ACC [5].
The poor response of ACC to conventional cytotoxic
agents has driven research into targeted molecular
t h e r a p i e s ,i nt h eh o p et h a tt h e ym a yp r o v i d em o r eb e n -
efit for patients with metastatic ACC. C-Kit proto-
oncogene, epidermal growth factor receptor (EGFR),
human epidermal receptor 2 proto-oncogene, androgen
receptors, p53 protein and VEGF are examples of
recent targets that have been evaluated with varying
degrees of expression in ACC. Kit is a transmembrane
cell surface receptor encoded by the c-Kit proto-onco-
gene. Its role is to regulate cell growth, differentiation,
and migration, and it is expressed in 65% to 100% of
ACC [4]. Because of its overexpression, it was thought
that imatinib, a TKI with activity against the c-Kit
receptor, could provide benefit in patients with ACC.
Unfortunately, a prospective study which included 16
ACC patients treated with imatinib demonstrated no
response to this therapy [6]. Another study showed
that imatinib might actually promote tumor progres-
sion in ACC [7].
Another potential target is the Her-2 receptor; its
expression in ACC has been shown to be extremely
variable with reports of anywhere from 4% to 100% of
patients. The use of trastuzumab, a monoclonal anti-
body directed against the Her-2 receptor, has also been
explored. Unfortunately, the results with this therapy
have also been disappointing. A phase II study that
enrolled 14 patients with advanced salivary gland
tumors demonstrated partial response with trastuzu-
mab in only one patient with mucoepidermoid carci-
noma. The two patients in this study with ACC did not
experience any benefits [8]. Other potential targets
such as EGFR and VEGF have also been found to be
variable in ACC.
Figure 4 CT scan demonstrating progression of disease after
second line palliative chemotherapy with carboplatin and
docetaxel.
Figure 5 CT scan demonstrating stable disease after five
months of sorafenib.
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Targeted therapy against molecular targets has not been
sufficiently evaluated in patients with ACC. To date,
ACC has shown poor response to targeted therapies. In
our case, our patient attained clinical benefit from sora-
fenib by obtaining a truly stable disease after twice pro-
gressing on active therapy. Sorafenib may have potential
for activity in these tumors because it targets several dif-
ferent cellular pathways, and since it appears that these
tumors are extremely variable in terms of the molecules
they express, a broader approach to these targets seems
to be reasonable.
Our patient appears to have classic tumor behavior for
ACC; presence of metastatic disease and chemoresis-
tance. The disease stabilization attained by our patient
with single agent sorafenib is exciting. It also demon-
strates that more research must been done to under-
stand the molecular mechanisms that are involved in
ACC and the potential targets for future therapy
development.
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